Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update

The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment, Development, and Evaluation system, which was published in October 2017 in Japanese. New or revised recommendations were described, herein, with a special reference to the surveillance, diagnostic, and treatment algorithms.

[1]  M. Kudo,et al.  Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). , 2017 .

[2]  M. Kudo,et al.  Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. , 2016, Journal of hepatology.

[3]  W. Lau,et al.  Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria , 2016, The British journal of surgery.

[4]  S. Kawasaki,et al.  Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  M. Kudo,et al.  Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan , 2013, British Journal of Cancer.

[6]  Osamu Matsui,et al.  Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. , 2013, Journal of hepatology.

[7]  C. Porta,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.

[8]  F. Xia,et al.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. , 2012, Journal of hepatology.

[9]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[10]  Yong Zeng,et al.  A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.

[11]  S. Kawasaki,et al.  The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma , 2010 .

[12]  Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update. , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[14]  Yutaka Matsuyama,et al.  Development of evidence‐based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  Masatoshi Kudo,et al.  Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Manual Proposed by the Japan Society of Hepatology , 2007, Oncology.

[16]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[17]  M. Makuuchi,et al.  Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. , 2006, World journal of gastroenterology.

[18]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.